FDA Inspection 1220498 — Ipsen
The FDA completed an inspection of Ipsen on March 30, 2023 in Les Ulis Cedex. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 30, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Les Ulis Cedex (France)
Additional Details
Postmarket Adverse Drug Experience (PADE)